News

Katie Motherway Katie Motherway

Access Vascular Supports Updated Standards of Care Emphasizing New Materials to Reduce Catheter Complications

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Read More
Katie Motherway Katie Motherway

Access Vascular to Ramp Production With $22 Million Series C Financing

“AVI is poised to have a substantial impact on vascular access complications and their associated costs,” said James Biggin, founder and CEO of Access Vascular. “This funding, coupled with increasing demand for our ground-breaking catheters, and new data showing reduced bacterial adhesion, is yet another milestone on our path to transforming the standard of care for vascular access.”

Read More
Katie Motherway Katie Motherway

Access Vascular Highlights New Bacterial Adhesion Data at AVA 2023

The study, results of which were shared Oct. 14 at the annual scientific meeting of the Association for Vascular Access, compared bacterial adhesion on two polyurethane-based catheters and the HBM using in vitro blood flow and static models. The HBM demonstrated a 99.998 percent reduction in bacterial adhesion compared with the standard polyurethane catheter, and a 99.989 percent reduction compared with an augmented polyurethane material.

Read More
Katie Motherway Katie Motherway

Access Vascular Integrative Review Published in International Journal of Nursing and Healthcare Research Establishes Economic Impact of Biomaterial Catheters

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared key findings from an economic analysis published in the International Journal of Nursing and Research regarding AVI’s consistently hydrophilic PICC and midline catheters. The analysis documents millions of dollars in available cost-savings for hospitals using biomaterial-based catheters to reduce vascular access complications.

Read More
Katie Motherway Katie Motherway

Journal of Infusion Nursing Publishes Access Vascular Data Showing Significantly Reduced Complication Rates for HydroMID

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today announced the outcome of a peer-reviewed study published in the Journal of Infusion Nursing that demonstrated a significant reduction in complications when using AVI’s consistently hydrophilic midline catheters.

Read More
Katie Motherway Katie Motherway

Access Vascular Inc. Named 2022 MedTech Breakthrough Award Winner

Access Vascular, Inc. (AVI) today announced it has been named “Best New Technology Solution – Drug Delivery” in the 2022 MedTech Breakthrough Awards. AVI’s patented, groundbreaking new biomaterial-based catheters were recognized for their potential to reshape the field of vascular access and value based care at large.

Read More
Katie Motherway Katie Motherway

Access Vascular Receives FDA Clearance for HydroPICC® Biomaterial-Based Dual-Lumen Catheter

Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC® Dual-Lumen catheter. Designed and constructed using the same proprietary hydrophilic biomaterial as AVI’s single-lumen HydroPICC® and HydroMID® catheters, these devices showed significant reduction in complications such as occlusions, replacements, Deep Vein Thrombosis and phlebitis in recent studies.

Read More
Katie Motherway Katie Motherway

Access Vascular Inc. Named 2022 BIG Innovation Award Winner

AVI’s groundbreaking new biomaterial-based cathethers were recognized for their ability to nearly eliminate the common and expensive complications that affect approximately 30% of all hospital patients with traditional polyurethane catheters inserted. This transformational technology has the potential to reshape the field of vascular access and value based care at large.

Read More
Katie Motherway Katie Motherway

Access Vascular Inc. and Eloquest Healthcare Partner to Improve Vascular Access Outcomes

“Eloquest Healthcare is known for delivering innovative solutions that improve the standard of care with an emphasis on infection prevention and enhanced patient satisfaction, making them a perfect partner for Access Vascular,” said James Biggins, CEO at Access Vascular Inc. “Our mission is to eliminate complications like catheter thrombosis, phlebitis and resulting infections, thereby improving the efficacy of vascular access procedures. This partnership will help us carry that mission further and faster.”

Read More
Katie Motherway Katie Motherway

New Access Vascular Clinical Studies Find Catheters Composed of Advanced Biomaterials Significantly Reduce Complication Rates

Data presented at the AVA Annual Scientific Meeting shows impactful reductions in occlusions, DVT, and phlebitis using materials that mimic the body’s chemistry

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared initial findings from two new clinical studies that demonstrate a significant reduction in complications when using AVI’s consistently hydrophilic materials for peripherally inserted central catheters (PICC) and midline catheters.

Read More
Katie Motherway Katie Motherway

Access Vascular Inc. and Association for Vascular Access partner to champion clinicians leading care transformation at their institutions

Despite incremental changes to catheter design and placement techniques, catheter related complication rates remain unacceptably high and range between 30% and 34%1,2. Complications such as catheter related thrombosis, phlebitis and infections impact patient safety, increase total medical costs, and create frustration for clinicians.

Read More
Katie Motherway Katie Motherway

Access Vascular, Inc. Secures $20 Million in Series B Financing

Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. TVM Capital Life Science led the round with a $15 million commitment, with existing investors also participating.

Read More
Katie Motherway Katie Motherway

HydroMID Midline Catheter from Access Vascular Receives FDA Clearance

Access Vascular, Inc. today announced FDA clearance of its HydroMID™ midline catheter. HydroMID, which is made of Access Vascular’s proprietary biomaterial that has been shown to reduce thrombus accumulation by up to 97 percent when compared to standard polyurethane catheters,1 is the second device in its planned portfolio to obtain clearance.

Read More